Whalesbook
Strategic Analysis & Impact
Dr. Agarwal's Health Care Limited (AHCL) has taken a significant step forward in its proposed amalgamation with Dr. Agarwal’s Eye Hospital Limited (AEHL), securing crucial 'no adverse observations' from BSE Limited and a 'no objection' letter from the National Stock Exchange of India (NSE). These approvals, dated February 16-17, 2026, are vital milestones in the complex process of merging the two entities under the Dr. Agarwal's Group.
The amalgamation is expected to consolidate the businesses of AHCL and AEHL into a single, more robust entity. The stated goals include achieving operational and financial efficiencies through streamlined functions, agile decision-making, unified capital allocation, and a stronger balance sheet to support future growth. Management has indicated the merger is expected to be EPS accretive from the first year of implementation, enhancing shareholder value. The scheme of amalgamation involves AHCL issuing 23 new equity shares for every 2 equity shares held by eligible AEHL shareholders, excluding AHCL's existing stake. AEHL has also approved a preferential issue of approximately ₹70 crore. AHCL itself is a relatively new listed entity, having debuted on the stock exchanges in February 2025, with its IPO prospectus indicating an intention to explore such a merger within three years.
Risks & Outlook
While the BSE and NSE approvals are significant, the amalgamation is still subject to final clearances from the National Company Law Tribunal (NCLT), as well as approvals from the shareholders and creditors of both companies. The process can be lengthy and complex, with potential for integration challenges post-merger. SEBI has also provided specific comments and conditions that AHCL must adhere to, which were detailed in the NSE observation letter, suggesting ongoing regulatory scrutiny. The company is also in a high-growth phase, with plans to add 55-60 new facilities and already operating a large network of 272 facilities as of December 2025. Successfully integrating the merged entities while continuing this expansion will be key.
Negative History:
In 2013, Dr. Agarwal's Eye Hospital Limited faced regulatory action from SEBI for failing to meet the minimum public shareholding (MPS) norms within the stipulated deadline. SEBI had imposed restrictions, including freezing voting rights and corporate benefits, before revoking them after the company complied by issuing shares through an Employees Stock Purchase Scheme (ESPS). This resulted in promoter holding reducing to 74.90% and public shareholders holding 25.10%, meeting the norms. The company was cautioned by SEBI to ensure future compliance with all applicable laws and regulations.
Peer Comparison
The Indian eye care sector is competitive and experiencing significant consolidation. Dr. Agarwal's Health Care claims to be India's largest eye care service chain by revenue, holding a market share of approximately 25% in FY2024, with the highest number of facilities. It recently reported strong Q3 FY26 performance with revenue growth of 23% YoY.
Competitors like Centre for Sight, which operates around 83 centers and reported revenue of ₹582 crore in FY25, are also expanding with PE backing. LV Prasad Eye Institute (LVPEI), a non-profit, is one of the world's largest eye-care networks with over 300 centers, providing significant community outreach and research. Vasan Eye Care, though acquired by ASG Eye Hospitals in March 2023, historically had a substantial network and revenue. The sector is characterized by high margins, with EBITDA margins for eye-care chains being 5-10% higher than other specialty players. The current merger aims to strengthen AHCL's position amidst this dynamic and growing market.